| |
| Device | FoundationOne CDx |
| Generic Name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Foundation Medicine, Inc. 400 Summer St. Boston, MA 02210 |
| PMA Number | P170019 |
| Supplement Number | S032 |
| Date Received | 03/01/2021 |
| Decision Date | 05/06/2022 |
| Product Code |
PQP |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track No User Fee |
| Supplement Reason | Postapproval Study Protocol |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the clinical protocol entitled F1CDx Validation Protocol and Statistical Analysis Plan: NTRK Clinical Efficacy Post Approval Study for larotrectinib |